Drugs / 9MW2821
9MW2821
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06551233 | Apr → Nov 2024 overdue | urinary bladder cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 1 | NCT05773937 | Jun 2022 → Dec 2024 overdue | cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07615660 | May 2026 → Apr 2029 expected | neoplastic disease or syndrome | Convalife (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06926998 | Apr 2025 → May 2027 expected | female reproductive organ cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06947226 | Apr 2025 → Apr 2026 overdue | cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06079112 | Sep 2023 → Dec 2026 expected | urothelial carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07412171 | Feb 2026 → Dec 2028 expected | renal pelvis/ureter urothelial carcinoma | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07045311 | Sep 2025 → Mar 2028 expected | triple-negative breast carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07314723 | Aug 2025 → Dec 2027 expected | urothelial carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06649331 | Oct 2024 → Sep 2026 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06492005 | Jul 2024 → Jul 2026 overdue | triple-negative breast carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07556848 | May 2026 → Dec 2027 expected | triple-negative breast carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06592326 | Aug 2024 → Sep 2027 expected | urothelial carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06823427 Background | Jan 2025 → Jun 2026 overdue | renal pelvis/ureter urothelial carcinoma, urinary bladder carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9MW2821 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06079112 ↗ |
| Known as | BFv | “Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate” PMID 40288679 ↗ Apr 2025 |
| Known as | Bulumtatug Fuvedotin | “Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate” PMID 40288679 ↗ Apr 2025 |
| Modality | Monoclonal antibody | “a Nectin-4 antibody-drug conjugate (ADC)” NCT05582499 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT05773937 ↗ |